ArticleCell death discovery2026
The protective up-regulation of metallothionein-2A in intervertebral disc degeneration inhibits nucleus pulposus cell ferroptosis through activation of the PI3K/AKT/mTOR pathway.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Intervertebral disc degeneration (IVDD) is a major contributor to low back pain, influenced by various factors including cellular senescence, apoptosis, oxidative stress, and inflammation. Metallothionein-2A (MT2A), due to its unique metal-binding and antioxidant capacity, plays a critical role in various diseases. This research sought to clarify how MT2A inhibits the progression of IVDD. Single-cell sequencing analysis revealed that ferroptosis was involved in IVDD, and MT2A was significantly upregulated in the degenerated nucleus pulposus tissue. In vitro, Tert-Butyl Hydroperoxide (TBHP) treatment induced MT2A expression. Knockdown of MT2A exacerbated TBHP-induced ferroptosis, whereas MT2A overexpression or treatment with ferrostatin-1 reversed ferroptosis, lipid peroxidation, and mitochondrial damage. In vivo, AAV-mediated MT2A overexpression significantly alleviated puncture-induced IVDD in rats. Mechanistically, MT2A overexpression activated PI3K/AKT/mTOR pathway, and this protective effect was significantly attenuated upon treatment with specific pathway inhibitors. In Conclusion, our findings demonstrate that MT2A is protectively upregulated in IVDD and mitigates ferroptosis of NP cells and IVDD progression through activation of the PI3K/AKT/mTOR pathway, which designates MT2A as a promising target for therapy in IVDD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.